<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80765">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02101047</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 26872</org_study_id>
    <nct_id>NCT02101047</nct_id>
  </id_info>
  <brief_title>Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension</brief_title>
  <official_title>Correlation and Effects on Cardiac Output With Intermittent Phenylephrine Administration of 50 mcg Versus 100 mcg or 100mcg/Min Prophylactic Infusion for Treatment of Hypotension in Parturients After Receiving Spinal Anesthesia for Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three different regimens of phenylephrine are being evaluated to see if one is superior over
      the other in the maintenance of cardiac output while keeping normotension and/or treating
      hypotension experienced when receiving spinal anesthesia for cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenylephrine will be administered in one of 3 regimens:  Intermittent bolus of 50 mcg,
      Intermittent bolus of 100 mcg, or continuous infusion of 100 mcg/min.  The infusion will
      contain either phenylephrine or normal saline (placebo). Subjects who are randomized to
      receive a bolus dose will receive placebo in the infusion.  Subjects who are randomized to
      receive the phenylephrine infusion will have normal saline (placebo) in the bolus syringe.
      Baseline blood pressures will be obtained prior to surgery and then maintained using these
      drugs.  Blood pressure and heart rate will be monitored as usual standard of care.
      Continuous cardiac output and hemodynamic monitoring will be obtained using CNAP (Tm) or
      similar (equivalent) monitoring device.   Blood pressure will be maintained at 90-120% of
      baseline utilizing infusion and/or bolus with the 3 regimens.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Magnitude of cardiac output changes</measure>
    <time_frame>0-90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Magnitude of cardiac output reduction for the duration from preoperative baseline from time of spinal anesthesia to delivery of fetus and placenta.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>provider intervention</measure>
    <time_frame>0-90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of provider intervention to treat abnormal hemodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vasopressor requirement</measure>
    <time_frame>0-90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>total amount of vasopressor or equivalent required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emetic symptoms</measure>
    <time_frame>0-90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>emetic symptoms - magnitude and/or incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypertension</measure>
    <time_frame>0-90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>incidence and magnitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypotension</measure>
    <time_frame>0-90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>incidence and magnitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bradycardia</measure>
    <time_frame>0-90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>incidence and magnitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthetic time</measure>
    <time_frame>up to 120 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Complications; Cesarean Section</condition>
  <condition>Spinal Anesthetics Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>phenylephrine 50mcg bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenylephrine 50 mcg bolus dosing with continuous placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine 100 mcg bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenylephrine 100 mcg bolus dosing wtih continuous placebo infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine continuous infusion 100mcg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous phenylephrine infusion of 100 mcg/min with placebo bolus dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <arm_group_label>phenylephrine 50mcg bolus</arm_group_label>
    <arm_group_label>Phenylephrine 100 mcg bolus</arm_group_label>
    <arm_group_label>Phenylephrine continuous infusion 100mcg/min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled for cesarean delivery age &gt;/=18 years of age &gt;/= 37 weeks EGA ASA status
             I-III

        Exclusion Criteria:

          -  allergy to medications used in the study non-English speaking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Pan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynnette Harris, BSN</last_name>
    <phone>336-718-6049</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Pan, MD</last_name>
    <phone>336-718-8278</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novant Health Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Pan, MD</last_name>
      <phone>336-718-8278</phone>
    </contact>
    <contact_backup>
      <last_name>Lynnette Harris, BSN</last_name>
      <phone>336-718-6049</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest School of Medicine</investigator_affiliation>
    <investigator_full_name>Dr. Peter H. Pan, M.D., MSEE</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>hypotension</keyword>
  <keyword>phenylephrine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
